Immix Biopharma Trial Results Selected for ASH Oral Presentation
Immix Biopharma said it will present NXC-201 interim NEXICART-2 trial results at ASH on Dec. 14, 2026, at 11:15 a.m. CDT.
Related stories
Air Travel Disruptions to Persist Into Sunday, Officials Say
Officials say thousands of flights have been affected, with air travel issues expected to persist well into Sunday.
M impact | EQUITY | Nov 14, 2026, 09:39 PM UTC
SpaceX Starship Returns to Texas Launch Tower After Orbital Flight
SpaceX’s Starship spacecraft returned Saturday to the Texas launch tower from which it launched a day earlier, completing the rocket system’s first key recovery, according to the r
M impact | EQUITY | Nov 14, 2026, 09:22 PM UTC
More Than 10,000 Flights Delayed or Canceled Saturday
Airlines are working to restore normal schedules.
M impact | EQUITY | Nov 14, 2026, 07:34 PM UTC
Flight Cancellations Mount at DFW and Love Field After FAA Ground Stop
Cancellations mounted Saturday morning at DFW International Airport and Dallas Love Field after an FAA ground stop was lifted.
M impact | EQUITY | Nov 14, 2026, 07:03 PM UTC
Thousands of US Flights Canceled and Delayed as Air Travel System Recovers
Thousands of US flights were canceled or delayed as the air travel system slowly recovered from a shutdown.
M impact | EQUITY | Nov 14, 2026, 06:37 PM UTC
Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound
The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC